The concept known as “arbitration” to resolve billing disputes between out-of-network providers and insurers on surprise medical bills could spell doom for the pharmaceutical industry if it is cross-walked into the prescription-drug debate.
Thirty-year pharma veteran Nancy Lurker shares her four pillars on which to build your business and why they are crucial to driving stakeholder value over the mid- to long-term.
Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.
Repeat entrepreneur is a term you might hear often in the context of life sciences company creation and investment, so we wanted to take a moment to unpack it and offer lessons for those on either side of the table.
Pharma companies can benefit from conducting war games by gaining a better understanding of the external opportunities and challenges of all the key stakeholders in the industry.
Robert Hariri, M.D., Ph.D., CEO of Celularity Therapeutics, shares how a biopharmaceutical industry CEO has come to know Hollywood celebrities.
Robert Hariri, M.D., Ph.D., CEO of Celularity, shares a story of an investor’s life being altered dramatically by an investment in one of his companies.
Bassil Dahiyat, Ph.D., president and CEO of Xencor, shares his perspective on why full-time equivalent (FTE) partnering deals are money losers.